The Effects of Anti-insulin Antibodies and Cross-reactivity with Human Recombinant Insulin Analogues in the E170 Insulin Immunometric Assay
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Insulin assays are affected by varying degrees of interference from anti-insulin antibodies (IAs) and by cross-reactivity with recombinant insulin analogues. We evaluated the usefulness of the E170 insulin assay by assessing IA effects and cross-reactivity with 2 analogues. Methods: Sera were obtained from 59 type 2 diabetes patients receiving continuous subcutaneous insulin infusion and 18 healthy controls. Insulin levels were determined using an E170 analyzer. To investigate the effects of IAs, we performed IA radioimmunoassays,and analyzed the differences between directly measured insulin (direct insulin) and polyethylene glycol (PEG)-treated insulins (free, IA-unbound; total, IA-bound and unbound insulin). We performed in-vitro cross-reactivity tests with insulin aspart and insulin glulisine. Results: In IA-positive patients, E170 free insulin levels measured using the E170 analyzer were significantly lower than the direct insulin levels. The mean value of the direct/free insulin ratio and IA-bound insulin, which were calculated as the difference between total and free insulin, increased significantly as endogenous IA levels increased. The E170 insulin assay showed low cross-reactivities with both analogues (< 0.7%). Conclusions: IAs interfered with E170 insulin assay, and the extent of interference correlated with the IA levels, which may be attributable to the increase in IA-bound insulin, and not to an error in the assay. The E170 insulin assay may measure only endogenous insulin since cross-reactivity is low. Our results suggest that the measurement of free insulin after PEG pre-treatment could be useful for β cell function assessment in diabetic patients undergoing insulin therapy.
Abstract
Background: Insulin assays are affected by varying degrees of interference from anti-insulin antibodies (IAs) and by cross-reactivity with recombinant insulin analogues. We evaluated the usefulness of the E170 insulin assay by assessing IA effects and cross-reactivity with 2 analogues. Methods: Sera were obtained from 59 type 2 diabetes patients receiving continuous subcutaneous insulin infusion and 18 healthy controls. Insulin levels were determined using an E170 analyzer. To investigate the effects of IAs, we performed IA radioimmunoassays,and analyzed the differences between directly measured insulin (direct insulin) and polyethylene glycol (PEG)-treated insulins (free, IA-unbound; total, IA-bound and unbound insulin). We performed in-vitro cross-reactivity tests with insulin aspart and insulin glulisine. Results: In IA-positive patients, E170 free insulin levels measured using the E170 analyzer were significantly lower than the direct insulin levels. The mean value of the direct/free insulin ratio and IA-bound insulin, which were calculated as the difference between total and free insulin, increased significantly as endogenous IA levels increased. The E170 insulin assay showed low cross-reactivities with both analogues (< 0.7%). Conclusions: IAs interfered with E170 insulin assay, and the extent of interference correlated with the IA levels, which may be attributable to the increase in IA-bound insulin, and not to an error in the assay. The E170 insulin assay may measure only endogenous insulin since cross-reactivity is low. Our results suggest that the measurement of free insulin after PEG pre-treatment could be useful for β cell function assessment in diabetic patients undergoing insulin therapy.
참고문헌 (25)
- Sapin R, "Insulin immunoassays: fast approaching 50 years of existence and still calling for standardization", Clin Chem, 53, pp.810~812 (2007)
- Radermecker RP, "Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control", Diabetes Metab Res Rev, 25, pp.491~501 (2009)
- Sapin R, "Insulin assays: previously known and new analytical features", Clin Lab, 49, pp.113~121 (2003)
- Walker JM, "The protein protocols handbook. 2nd ed", pp.991~992 (2002), Humana Press
- Kuzuya H, "Determination of free and total insulin and C-peptide in insulin-treated diabetics", Diabetes, 26, pp.22~29 (1977)
- Gennaro WD, "Quantitation of free, total, and antibody- bound insulin in insulin-treated diabetics", Clin Chem, 21, pp.873~879 (1975)
- Armitage M, "Insulin autoantibodies and insulin assay", Diabetes, 37, pp.1392~1396 (1988)
- Sapin R, "Anti-insulin antibodies in insulin immunometric assays: a still possible pitfall", Eur J Clin Chem Clin Biochem, 35, pp.365~367 (1997)
- Sapin R, "The interference of insulin antibodies in insulin immunometric assays", Clin Chem Lab Med, 40, pp.705~708 (2002)
- Hanning I, "Measurement of free insulin concentrations: the influence of the timing of extraction of insulin antibodies", Diabetologia, 28, pp.831~835 (1985)
- The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus", N Engl J Med, 329, pp.977~986 (1993)
- Jeandidier N, "Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices", Diabetologia, 38, pp.577~584 (1995)
- Fineberg SE, "Immunological responses to exogenous insulin", Endocr Rev, 28, pp.625~652 (2007)
- Owen WE, "Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays", Clin Chem, 50, pp.257~259 (2004)
- Ibrahim F, "Differences in circulating insulin levels following glargine administration", Clin Biochem, 41, pp.429~431 (2008)
- Becker RH, "Insulin glulisine complementing basal insulins: a review of structure and activity", Diabetes Technol Ther, 9, pp.109~121 (2007)
- De Meyts P, "Insulin and its receptor: structure, function and evolution", Bioessays, 26, pp.1351~1362 (2004)
- Devendra D, "The use of phage display to distinguish insulin autoantibody (IAA) from insulin antibody (IA) idiotypes", Diabetologia, 46, pp.802~809 (2003)
- 김혜련, "제 2형 당뇨병 환자에서 Tumor Necrosis Factor-α유전자 -308과 -238의 다형성 분석", Annals of Laboratory Medicine, 26(1), pp.58~63 (2006), 대한진단검사의학회
- Berson SA, "Quantitative aspects of the reaction between insulin and insulin-binding antibody", J Clin Invest, 38, pp.1996~2016 (1959)
- Kahn CR, "Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome", Diabetes Care, 2, pp.283~295 (1979)
- Grunfeld C, "Insulin resistance: pathophysiology, diagnosis, and therapeutic implications", Spec Top Endocrinol Metab, 6, pp.193~240 (1984)
- Davidson JK, "Immunologic insulin resistance", Diabetes, 27, pp.307~318 (1978)
- Arnqvist H, "Free and total insulin as determined after precipitation with polyethylene glycol: analytical characteristics and effects of sample handling and storage", Clin Chem, 33, pp.93~96 (1987)
- Peluso I, "Separation of free and antibodybound insulin in plasma using a bench ultracentrifuge (Beckman ‘Airfuge’)", Clin Chim Acta, 139, pp.317~320 (1984)